STAT5B

Summary

STAT5B (signal transducer and activator of transcription 5B, HGNC:11367) is a protein-coding gene on chromosome 17q21.2, encoding Signal transducer and activator of transcription 5B (P51692). Carries out a dual function: signal transduction and activation of transcription.

The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein mediates the signal transduction triggered by various cell ligands, such as IL2, IL4, CSF1, and different growth hormones. It has been shown to be involved in diverse biological processes, such as TCR signaling, apoptosis, adult mammary gland development, and sexual dimorphism of liver gene expression. This gene was found to fuse to retinoic acid receptor-alpha (RARA) gene in a small subset of acute promyelocytic leukemias (APLL). The dysregulation of the signaling pathways mediated by this protein may be the cause of the APLL.

Source: NCBI Gene 6777 — RefSeq curated summary.

At a glance

• Gene–disease (curated): growth hormone insensitivity with immune dysregulation 1, autosomal recessive (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 18
• Clinical variants (ClinVar): 601 total — 26 pathogenic, 6 likely-pathogenic
• Phenotypes (HPO): 57
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• Transcription factor: yes — 112 downstream targets (CollecTRI)
• MANE Select transcript: NM_012448

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11367
Approved symbol	STAT5B
Name	signal transducer and activator of transcription 5B
Location	17q21.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000173757
Ensembl biotype	protein_coding
OMIM	604260
Entrez	6777

Gene structure

Transcript identifiers

Ensembl transcripts: 45 — 23 protein_coding, 13 retained_intron, 9 nonsense_mediated_decay

ENST00000293328, ENST00000415845, ENST00000468312, ENST00000468496, ENST00000481253, ENST00000481517, ENST00000498674, ENST00000698774, ENST00000698775, ENST00000698776, ENST00000698777, ENST00000698778, ENST00000698779, ENST00000698801, ENST00000698802, ENST00000698803, ENST00000698804, ENST00000698805, ENST00000698806, ENST00000698807, ENST00000698808, ENST00000698809, ENST00000698810, ENST00000698811, ENST00000698812, ENST00000698813, ENST00000698814, ENST00000698815, ENST00000698816, ENST00000698817, ENST00000903577, ENST00000903578, ENST00000903579, ENST00000914413, ENST00000914414, ENST00000914415, ENST00000914416, ENST00000914417, ENST00000951701, ENST00000951702, ENST00000951703, ENST00000951704, ENST00000951705, ENST00000951706, ENST00000951707

RefSeq mRNA: 1 — MANE Select: NM_012448 NM_012448

CCDS: CCDS11423

Canonical transcript exons

ENST00000293328 — 19 exons

Exon	Start	End
ENSE00001293555	42199177	42201864
ENSE00001626332	42223382	42223556
ENSE00003659767	42227529	42227685
ENSE00003974711	42210403	42210497
ENSE00003974712	42217377	42217464
ENSE00003974713	42218723	42218878
ENSE00003974714	42211984	42212190
ENSE00003974715	42217160	42217282
ENSE00003974717	42218151	42218330
ENSE00003974718	42216014	42216106
ENSE00003974730	42207558	42207728
ENSE00003974731	42202340	42202447
ENSE00003974732	42224779	42224868
ENSE00003974734	42202757	42202808
ENSE00003974738	42210171	42210301
ENSE00003974740	42219712	42219842
ENSE00003974826	42219312	42219463
ENSE00003974835	42276248	42276391
ENSE00003974841	42232000	42232137

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 97.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.7245 / max 399.4841, expressed in 1786 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166124	13.1179	1784
166125	0.3569	99
166123	0.2497	91

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	97.52	gold quality
body of uterus	UBERON:0009853	96.77	gold quality
left uterine tube	UBERON:0001303	96.64	gold quality
right ovary	UBERON:0002118	96.40	gold quality
left ovary	UBERON:0002119	96.31	gold quality
type B pancreatic cell	CL:0000169	96.11	gold quality
paraflocculus	UBERON:0005351	96.11	gold quality
frontal pole	UBERON:0002795	95.87	gold quality
granulocyte	CL:0000094	95.36	gold quality
middle frontal gyrus	UBERON:0002702	95.30	gold quality
endocervix	UBERON:0000458	95.26	gold quality
left adrenal gland cortex	UBERON:0035825	95.25	gold quality
left adrenal gland	UBERON:0001234	95.08	gold quality
mucosa of stomach	UBERON:0001199	95.05	gold quality
right adrenal gland	UBERON:0001233	95.00	gold quality
cerebellar hemisphere	UBERON:0002245	94.85	gold quality
cerebellar cortex	UBERON:0002129	94.80	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.79	gold quality
gastrocnemius	UBERON:0001388	94.77	gold quality
lymph node	UBERON:0000029	94.71	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.69	gold quality
myometrium	UBERON:0001296	94.65	gold quality
muscle of leg	UBERON:0001383	94.63	gold quality
right adrenal gland cortex	UBERON:0035827	94.63	gold quality
adrenal cortex	UBERON:0001235	94.57	gold quality
cerebellum	UBERON:0002037	94.54	gold quality
adrenal gland	UBERON:0002369	94.49	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.48	gold quality
bone marrow cell	CL:0002092	94.26	gold quality
right coronary artery	UBERON:0001625	94.24	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.32

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

112 targets.

Target	Regulation
A2M
AGT	Unknown
AKR1C1	Unknown
ANP32A	Activation
APOC3	Activation
AURKA
BCL2	Activation
BCL2L1	Activation
BCL6	Repression
CCND1	Unknown
CCND2	Activation
CCND3	Unknown
CD4	Unknown
CD84	Activation
CDK6
CDKN1A	Unknown
CDKN1B
CDKN2B
CEL	Unknown
CHORDC1	Activation
CISH	Activation
CITED2
CREBBP
CSF2	Activation
CSN1S1	Activation
CSN2	Activation
CXCL8	Unknown
CXCL9	Activation
CYP21A1P
CYP8B1	Activation

Upstream regulators (CollecTRI, top): CEBPA, CEBPB, CEBPG, NFKB, PPARA, STAT5A, STAT5B, ZNF382

miRNA regulators (miRDB)

101 targeting STAT5B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-129-5P	99.88	70.26	3273

Literature-anchored findings (GeneRIF, showing 40)

• The data presented here demonstrate that, in contrast to activation by the cytokine, growth hormone (GH), the activation of STAT5b by the growth factor, epidermal growth factor (EGF), requires overexpression of the EGF receptor (EGFR). (PMID:11751923)
• STAT5 isoform expression, GM-CSF-induced STAT5 activation, and STAT5 target-gene expression are altered significantly during monocyte/macrophage differentiation (PMID:11867689)
• increase in Cyclin D1 promoter activity is predominantly mediated by the Jak2/Stat5 signaling pathway. PRL induces Stat5a and 5b to bind to Cyclin D1 promoter (PMID:11923474)
• Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with STAT3 and STAT5 signaling pathways. (PMID:11929748)
• Oligomerization of the coiled-coil domain of Stat5 in the Stat5-RARalpha fusion protein leads to stable binding of the corepressor SMRT and is accompanied by an impaired response to differentiation signals in hematopoietic cell (PMID:11929749)
• Up-regulation of RFC2 and the kinase pim-1 by BCR/ABL requires activation of STAT5b by signaling from SH3+SH2 domains of BCR/ABL. (PMID:12036885)
• Our study thus suggests a functional cooperation between AR and Stat5. (PMID:12089361)
• No evidence was found for STAT5b rearrangement at the chromosomal or molecular levels in primary leukemias. STAT5 activation is probably a secondary event in most leukemias. (PMID:12145702)
• CPAP was found to augment Stat5-mediated transcription. (PMID:12198240)
• Signal transducer and activator of transcription (Stat)5a and Stat5b are critical for normal immune function. (PMID:12377952)
• role in mediating synergism between c-src and epidermal growth factor receptor (PMID:12429742)
• role in suppressing transcriptional activity of estrogen receptors and inducing apoptosis in breast cancer cells (PMID:12642867)
• Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5 in regulation of eosinophil apoptosis by nitric oxide. (PMID:12847485)
• Stat5 plays an important role in IFN-signaling and participates in the induction of Type I IFN-dependent responses. (PMID:12901872)
• In tissues from 33 individuals with head and neck cancer, Stat5 activation levels were correlated with progression to a malignant phenotype. (PMID:14583472)
• Mpl-L-treated Stat5b-deficient mice demonstrated significantly delayed hematopoietic recovery, while Stat5b-deficient mice did not (PMID:14662325)
• diminished N-domain-mediated oligomerization affected transcriptional activation by both Stat1 and Stat5a/b in a promoter-specific manner. (PMID:15010467)
• Crossing the STAT5b constitutively active transgene onto the IL-7 receptor-deficient background restores immature B and mature B cell populations as seen by significant increases of immature B and mature B cells. (PMID:15067053)
• Stat5B is activated by pathways involving FGFR3 and Pyk2 (PMID:15105428)
• Perturbation of STAT5a&b expression by addition of ODNs decreased proliferative potential of the CML and the AML blasts as well as enhanced their apoptosis (PMID:15128421)
• requisite role of the Jak2/Stat5B pathway in mediating episodic growth hormone regulation of CYP2C11 (PMID:15591245)
• Stat5 activation results in the induction of pax5 and bcl-xL in early thymic lymphoid progenitor cells and thereby redirects these cells down the B cell lineage. (PMID:15944278)
• Study shows that active Stat5 distinguished prostate cancer patients whose disease is likely to progress earlier; therefore, active Stat5 may be a useful marker for selection of more individualized treatment. (PMID:16115927)
• STAT5b may mediate the transcriptional activation of cyclin D1 after hypoxic stimulation. (PMID:16155412)
• IFNalpha induces the activation of STAT5 in melanoma cells, and in STAT5-overexpressing cells, this contributes to IFNalpha resistance. (PMID:16169484)
• Stat5b A630P mutant is an inactive transcription factor by virtue of its aberrant folding and diminished solubility triggered by a misfolded SH2 domain. (PMID:16303763)
• STAT5b is an inefficient signal transducer and transcription factor, the detrimental impact on signaling pathways important for normal growth and immunity explains, in part, the complex clinical phenotype of GH insensitivity and immune dysfunction (PMID:16464942)
• STAT5A and STAT5B may play significant roles in the growth and the process of apoptosis of selected human cutaneous T-cell lymphoma cells. (PMID:16502315)
• STAT5b and HNF4alpha exhibit bi-directional cross-talk that may augment HNF4alpha-dependent gene transcription while inhibiting STAT5b transcriptional activity via the inhibitory effects of HNF4alpha on JAK2 phosphorylation (PMID:16584384)
• STAT5 is a direct binding partner to EGFR and ErbB4. (PMID:16729043)
• Cytoskeleton plays an important role in STAT5 activation and translocation into the nucleus in MCF7 cells stimulated with EGF. (PMID:16765629)
• STAT5b activity in breast cancer cells is modulated by various mutations of tyrosines within the transactivation domain. (PMID:16772534)
• Data show that STAT5 binds in vivo to the NCAM2 intron in the NKL natural killer cell line and that this binding is induced by cytokines that activate STAT5. (PMID:16840779)
• Transgenic constitutively activated STAT5b-CA naive CD4+ T cells display a 4-fold greater expression of IL-15 receptor alpha chain on their surface when compared with wild-type T cells. (PMID:16887981)
• STAT5b propagates an important IL-2-mediated signal for the in vivo accumulation of functional regulatory T cells (PMID:16920911)
• Therapeutic activation of the GH:STAT5b axis therefore represents a novel target for restoring both normal anabolic metabolism and mucosal tolerance in CD. (PMID:17148664)
• STAT5 expression was elevated in nasal NK/T cell lymphoma. (PMID:17225522)
• Defective STAT5b is an etiology for IGF deficiency and the growth hormone insensitivity phenotype. (PMID:17389811)
• ability of prolactin to activate Stat5 and activating protein-1 was inversely related in mammary cell lines (PMID:17438530)
• in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating (i) activation and nuclear translocation of STAT5 and p53 and (ii) an increased Bax/Bcl-2 ratio (PMID:17471233)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	stat5a	ENSDARG00000019392
danio_rerio	stat5b	ENSDARG00000055588
mus_musculus	Stat5b	ENSMUSG00000020919
rattus_norvegicus	Stat5b	ENSRNOG00000019075
drosophila_melanogaster	Stat92E	FBGN0016917

Paralogs (6): STAT1 (ENSG00000115415), STAT5A (ENSG00000126561), STAT4 (ENSG00000138378), STAT6 (ENSG00000166888), STAT3 (ENSG00000168610), STAT2 (ENSG00000170581)

Protein

Protein identifiers

Signal transducer and activator of transcription 5B — P51692 (reviewed: P51692)

All UniProt accessions (11): P51692, A0A8V8TM84, A0A8V8TM91, A0A8V8TMA6, A0A8V8TMP4, A0A8V8TMQ6, A0A8V8TMR0, A0A8V8TP00, A0A8V8TP16, A0A8V8TP21, C9J4I3

UniProt curated annotations — full annotation on UniProt →

Function. Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription. Positively regulates hematopoietic/erythroid differentiation.

Subunit / interactions. Upon activation, forms homodimers. Forms also heterodimers with related family members. Binds NR3C1. Interacts with NCOA1. Interacts with NMI. Interacts with SOCS7. Interacts (via SH2 domain) with INSR. Interacts with CPEB3; this inhibits STAT5B-mediated transcriptional activation.

Subcellular location. Cytoplasm. Nucleus.

Post-translational modifications. Tyrosine phosphorylated in response to signaling via activated KIT, resulting in translocation to the nucleus. Tyrosine phosphorylated in response to signaling via activated FLT3; wild-type FLT3 results in much weaker phosphorylation than constitutively activated mutant FLT3. Alternatively, can be phosphorylated by JAK2. Phosphorylation at Tyr-699 by PTK6 or HCK leads to an increase of its transcriptional activity.

Disease relevance. Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive (GHISID1) [MIM:245590] An autosomal recessive form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. Most, but not all, patients have features of immune dysregulation. The disease is caused by variants affecting the gene represented in this entry. Growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant (GHISID2) [MIM:618985] An autosomal dominant form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. GHISID2 patients usually have delayed bone age, delayed puberty, and decreased serum IGF1. Some patients may have features of mild immune dysregulation, such as eczema, increased serum IgE, asthma, or celiac disease. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the transcription factor STAT family.

RefSeq proteins (1): NP_036580* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR001217	STAT	Family
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR012345	STAT_TF_DNA-bd_N	Homologous_superfamily
IPR013799	STAT_TF_prot_interaction	Domain
IPR013800	STAT_TF_alpha	Domain
IPR013801	STAT_TF_DNA-bd	Domain
IPR015988	STAT_TF_CC	Homologous_superfamily
IPR035858	STAT5a/5b_DBD	Domain
IPR035886	STAT5b_SH2	Domain
IPR036535	STAT_N_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR046994	STAT5_CC	Domain
IPR048988	STAT_linker	Domain

Pfam: PF00017, PF01017, PF02864, PF02865, PF21354

UniProt features (58 total): helix 18, strand 17, sequence variant 6, turn 6, modified residue 5, mutagenesis site 2, chain 1, domain 1, sequence conflict 1, region of interest 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6MBZ	X-RAY DIFFRACTION	3.21
6MBW	X-RAY DIFFRACTION	3.29

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51692-F1	85.90	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 90, 128, 193, 682, 699

Mutagenesis-validated functional residues (2):

Position	Phenotype
684	abolishes interaction with insr.
699	abolishes phosphorylation by hck.

Function

Pathways and Gene Ontology

Reactome pathways

38 pathways

ID	Pathway
R-HSA-1170546	Prolactin receptor signaling
R-HSA-1266695	Interleukin-7 signaling
R-HSA-1433557	Signaling by SCF-KIT
R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants
R-HSA-186763	Downstream signal transduction
R-HSA-2586552	Signaling by Leptin
R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling
R-HSA-8854691	Interleukin-20 family signaling
R-HSA-8983432	Interleukin-15 signaling
R-HSA-8985947	Interleukin-9 signaling
R-HSA-9020558	Interleukin-2 signaling
R-HSA-9020958	Interleukin-21 signaling
R-HSA-9027283	Erythropoietin activates STAT5
R-HSA-9645135	STAT5 Activation
R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
R-HSA-9674555	Signaling by CSF3 (G-CSF)
R-HSA-9702518	STAT5 activation downstream of FLT3 ITD mutants
R-HSA-9703465	Signaling by FLT3 fusion proteins
R-HSA-9705462	Inactivation of CSF3 (G-CSF) signaling
R-HSA-982772	Growth hormone receptor signaling
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)
R-HSA-1226099	Signaling by FGFR in disease
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-168256	Immune System
R-HSA-1839124	FGFR1 mutant receptor activation
R-HSA-186797	Signaling by PDGF
R-HSA-449147	Signaling by Interleukins
R-HSA-451927	Interleukin-2 family signaling

MSigDB gene sets: 681 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CELL_ACTIVATION, REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NATURAL_KILLER_CELL_DIFFERENTIATION, WWTAAGGC_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_ERYTHROCYTE_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_RESPONSE_TO_ESTRADIOL, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE

GO Biological Process (63): mitotic cell cycle (GO:0000278), luteinization (GO:0001553), natural killer cell differentiation (GO:0001779), natural killer cell proliferation (GO:0001787), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), defense response (GO:0006952), cell surface receptor signaling pathway via JAK-STAT (GO:0007259), female pregnancy (GO:0007565), lactation (GO:0007595), regulation of steroid metabolic process (GO:0019218), cytokine-mediated signaling pathway (GO:0019221), taurine metabolic process (GO:0019530), lipid storage (GO:0019915), B cell differentiation (GO:0030183), erythrocyte differentiation (GO:0030218), regulation of epithelial cell differentiation (GO:0030856), response to estradiol (GO:0032355), positive regulation of interleukin-2 production (GO:0032743), positive regulation of natural killer cell proliferation (GO:0032819), positive regulation of natural killer cell differentiation (GO:0032825), cellular response to hormone stimulus (GO:0032870), myeloid cell apoptotic process (GO:0033028), negative regulation of myeloid cell apoptotic process (GO:0033033), T cell differentiation in thymus (GO:0033077), erythropoietin-mediated signaling pathway (GO:0038162), regulation of multicellular organism growth (GO:0040014), positive regulation of multicellular organism growth (GO:0040018), positive regulation of activated T cell proliferation (GO:0042104), regulation of cell population proliferation (GO:0042127), natural killer cell mediated cytotoxicity (GO:0042267), progesterone metabolic process (GO:0042448), gamma-delta T cell differentiation (GO:0042492), T cell homeostasis (GO:0043029), response to peptide hormone (GO:0043434), positive regulation of B cell differentiation (GO:0045579), positive regulation of gamma-delta T cell differentiation (GO:0045588), negative regulation of erythrocyte differentiation (GO:0045647), positive regulation of erythrocyte differentiation (GO:0045648), positive regulation of mitotic cell cycle (GO:0045931)

GO Molecular Function (11): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), nuclear glucocorticoid receptor binding (GO:0035259), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), protein dimerization activity (GO:0046983), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (6): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), RNA polymerase II transcription regulator complex (GO:0090575)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
Interleukin-2 family signaling	4
Cytokine Signaling in Immune system	3
Signaling by Interleukins	3
Signaling by Receptor Tyrosine Kinases	1
FGFR1 mutant receptor activation	1
Signaling by PDGF	1
Signal Transduction	1
Signaling by Erythropoietin	1
FLT3 Signaling	1
Signaling by KIT in disease	1
Signaling by FLT3 ITD and TKD mutants	1
FLT3 signaling in disease	1
Signaling by CSF3 (G-CSF)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
lymphocyte differentiation	2
natural killer cell activation	2
regulation of DNA-templated transcription	2
binding	2
protein binding	2
cell cycle	1
mitotic nuclear division	1
female gonad development	1
ovulation cycle process	1
lymphocyte proliferation	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
response to stress	1
cell surface receptor signaling pathway via STAT	1
multi-organism reproductive process	1
multi-multicellular organism process	1
body fluid secretion	1
mammary gland development	1
milk ejection reflex	1
steroid metabolic process	1
regulation of lipid metabolic process	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
alkanesulfonate metabolic process	1
nutrient storage	1
B cell activation	1
myeloid cell differentiation	1
erythrocyte homeostasis	1
epithelial cell differentiation	1
regulation of cell differentiation	1
regulation of multicellular organismal development	1
response to lipid	1
response to oxygen-containing compound	1
positive regulation of cytokine production	1
interleukin-2 production	1
regulation of interleukin-2 production	1
natural killer cell proliferation	1
positive regulation of natural killer cell activation	1

Protein interactions and networks

STRING

3734 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STAT5B	JAK2	O60674	997
STAT5B	JAK1	P23458	986
STAT5B	CRKL	P46109	983
STAT5B	STAT3	P40763	968
STAT5B	JAK3	P52333	956
STAT5B	EPOR	P19235	947
STAT5B	TYK2	P29597	934
STAT5B	IL7	P13232	925
STAT5B	IL2	P01585	916
STAT5B	EGFR	P00533	907
STAT5B	EZH2	Q15910	901
STAT5B	GHR	P10912	897
STAT5B	IL7R	P16871	885
STAT5B	STAT1	P42224	879
STAT5B	CSF2	P04141	877

IntAct

126 interactions, top by confidence:

A	B	Type	Score
STAT5B	MRPS6	psi-mi:“MI:0915”(physical association)	0.670
STAT5A	PDHA1	psi-mi:“MI:0914”(association)	0.640
STAT5B	NMI	psi-mi:“MI:0915”(physical association)	0.630
NMI	STAT5B	psi-mi:“MI:0915”(physical association)	0.630
STAT5B	STAT5B	psi-mi:“MI:0407”(direct interaction)	0.620
ZNF410	STAT5B	psi-mi:“MI:0915”(physical association)	0.560
STAC	STAT5B	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	ZNF410	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	LGALS14	psi-mi:“MI:0915”(physical association)	0.560
SUOX	STAT5B	psi-mi:“MI:0915”(physical association)	0.560
USP2	STAT5B	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	CHAF1A	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	MED25	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	STAC	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	PIK3R3	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	TSSK3	psi-mi:“MI:0915”(physical association)	0.560
CDKN1A	STAT5B	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	LMO4	psi-mi:“MI:0915”(physical association)	0.560
STAT5B	RBBP4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (126): MCMBP (Co-fractionation), STAT5B (Co-fractionation), STAT5B (Affinity Capture-MS), DLAT (Affinity Capture-MS), DLD (Affinity Capture-MS), HIVEP1 (Affinity Capture-MS), PDHA1 (Affinity Capture-MS), PDHB (Affinity Capture-MS), PDHX (Affinity Capture-MS), MVP (Affinity Capture-MS), KANSL3 (Affinity Capture-MS), ASF1B (Affinity Capture-MS), PUS7L (Affinity Capture-MS), GHR (Co-localization), CTLA4 (Co-localization)

ESM2 similar proteins: A0M8U1, A6H6W9, A6QL63, F1LSG8, O14639, P42229, P42230, P42232, P51692, P52632, P97875, Q12800, Q13330, Q1RLU8, Q2PG42, Q4V860, Q5RAN1, Q5RBB8, Q5ZKV9, Q62599, Q6AYJ2, Q6GQW0, Q6NRB5, Q6NZH6, Q6ZUT9, Q78E65, Q7T2U9, Q7Z6J6, Q8BR65, Q8CI71, Q8K4B0, Q8K4G5, Q8K4Q0, Q8N122, Q8R3S6, Q8WYK2, Q95115, Q9D2N4, Q9ERA0, Q9H7L9

Diamond homologs: O02799, P40763, P42224, P42225, P42227, P42228, P42229, P42230, P42231, P42232, P51692, P52630, P52631, P52632, P61635, Q14765, Q19S50, Q62771, Q6DV79, Q764M5, Q7ZXK3, Q95115, Q9PVX8, Q9TUM3, Q9TUZ0, Q9TUZ1, Q9WVL2, B5X561, Q24151, Q54BD4, O00910, P42226, P52633, Q61AP6, Q7QDU4, Q70GP4, Q9NAD6

SIGNOR signaling

13 interactions.

A	Effect	B	Mechanism
NCOA1	up-regulates	STAT5B	binding
EGFR	up-regulates	STAT5B	phosphorylation
PTK6	up-regulates	STAT5B	phosphorylation
EGFR	“up-regulates activity”	STAT5B	phosphorylation
PTPN2	“down-regulates activity”	STAT5B	dephosphorylation
EPHA4	“up-regulates activity”	STAT5B	phosphorylation
LCK	“up-regulates activity”	STAT5B	phosphorylation
JAK2	up-regulates	STAT5B	phosphorylation
PTPN1	down-regulates	STAT5B	dephosphorylation
SRC	up-regulates	STAT5B	phosphorylation
PTPN1	“down-regulates activity”	STAT5B	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 62 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Growth hormone receptor signaling	5	56.6×	4e-06
Downstream signal transduction	5	45.3×	1e-05
Signaling by ALK in cancer	6	38.8×	3e-06
Signaling by ALK fusions and activated point mutants	7	25.0×	3e-06
Signaling by Interleukins	7	10.7×	2e-04
Diseases of signal transduction by growth factor receptors and second messengers	7	9.5×	3e-04
PIP3 activates AKT signaling	5	8.0×	6e-03
Cytokine Signaling in Immune system	7	6.8×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor signaling pathway via JAK-STAT	6	31.7×	1e-05
negative regulation of cell population proliferation	9	6.9×	7e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — OVT.

Clinical variants and AI predictions

ClinVar

601 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	26
Likely pathogenic	6
Uncertain significance	282
Likely benign	241
Benign	18

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1074067	NM_012448.4(STAT5B):c.121C>T (p.Gln41Ter)	Pathogenic
1394582	NM_012448.4(STAT5B):c.2065G>T (p.Glu689Ter)	Pathogenic
1408216	NM_012448.4(STAT5B):c.424_427del (p.Leu142fs)	Pathogenic
1453821	NM_012448.4(STAT5B):c.1009C>T (p.Gln337Ter)	Pathogenic
1686232	NM_012448.4(STAT5B):c.1718G>A (p.Trp573Ter)	Pathogenic
2003395	NM_012448.4(STAT5B):c.415C>T (p.Gln139Ter)	Pathogenic
2018391	NM_012448.4(STAT5B):c.16C>T (p.Gln6Ter)	Pathogenic
2119313	NM_012448.4(STAT5B):c.1749del (p.Lys583fs)	Pathogenic
2425815	NC_000017.10:g.(?40371710)(40371880_?)del	Pathogenic
2570987	NM_012448.4(STAT5B):c.2135_2139dup (p.Ala714Ter)	Pathogenic
2739237	NM_012448.4(STAT5B):c.89_90dup (p.Arg31fs)	Pathogenic
2840836	NM_012448.4(STAT5B):c.1213_1229del (p.Tyr405fs)	Pathogenic
2852676	NM_012448.4(STAT5B):c.303C>A (p.Cys101Ter)	Pathogenic
2869095	NM_012448.4(STAT5B):c.1906C>T (p.Gln636Ter)	Pathogenic
3384021	NM_012448.4(STAT5B):c.1892G>A (p.Trp631Ter)	Pathogenic
3641526	NM_012448.4(STAT5B):c.245del (p.Leu82fs)	Pathogenic
4718768	NM_012448.4(STAT5B):c.240_241del (p.Leu82fs)	Pathogenic
4804939	NM_012448.4(STAT5B):c.1183G>T (p.Glu395Ter)	Pathogenic
492931	NM_012448.4(STAT5B):c.1421A>G (p.Gln474Arg)	Pathogenic
522611	NM_012448.4(STAT5B):c.530A>C (p.Gln177Pro)	Pathogenic
5694	NM_012448.4(STAT5B):c.1888G>C (p.Ala630Pro)	Pathogenic
5695	NM_012448.4(STAT5B):c.1191dup (p.Asn398fs)	Pathogenic
5697	NM_012448.4(STAT5B):c.454C>T (p.Arg152Ter)	Pathogenic
5698	NM_012448.4(STAT5B):c.1680+1del	Pathogenic
579749	NM_012448.4(STAT5B):c.1102dup (p.Gln368fs)	Pathogenic
840661	NM_012448.4(STAT5B):c.1102del (p.Gln368fs)	Pathogenic
1066569	NM_012448.4(STAT5B):c.1906+1G>A	Likely pathogenic
2446384	NM_012448.4(STAT5B):c.1896G>T (p.Lys632Asn)	Likely pathogenic
2955379	NM_012448.4(STAT5B):c.1681-2A>G	Likely pathogenic
3067804	NM_012448.4(STAT5B):c.1474-2_1474delinsT	Likely pathogenic

SpliceAI

3936 predictions. Top by Δscore:

Variant	Effect	Δscore
17:42201860:CAGGG:C	acceptor_gain	1.0000
17:42201861:AGGG:A	acceptor_gain	1.0000
17:42201862:GGG:G	acceptor_gain	1.0000
17:42201863:GG:G	acceptor_gain	1.0000
17:42201865:C:CC	acceptor_gain	1.0000
17:42201865:C:CG	acceptor_loss	1.0000
17:42201866:T:C	acceptor_gain	1.0000
17:42201866:T:TC	acceptor_gain	1.0000
17:42202338:A:AC	donor_gain	1.0000
17:42202339:C:CC	donor_gain	1.0000
17:42202339:CTT:C	donor_gain	1.0000
17:42202341:T:TA	donor_gain	1.0000
17:42202377:CAG:C	donor_gain	1.0000
17:42202379:G:C	donor_gain	1.0000
17:42202443:CAAAC:C	acceptor_gain	1.0000
17:42202444:AAAC:A	acceptor_gain	1.0000
17:42202445:AAC:A	acceptor_gain	1.0000
17:42202446:AC:A	acceptor_gain	1.0000
17:42202447:CC:C	acceptor_gain	1.0000
17:42202448:C:CA	acceptor_loss	1.0000
17:42202448:C:CC	acceptor_gain	1.0000
17:42202449:T:A	acceptor_loss	1.0000
17:42202755:A:AC	donor_gain	1.0000
17:42202756:C:CC	donor_gain	1.0000
17:42202756:CT:C	donor_gain	1.0000
17:42202809:C:CC	acceptor_gain	1.0000
17:42207605:T:TA	donor_gain	1.0000
17:42207727:CT:C	acceptor_gain	1.0000
17:42207729:C:CC	acceptor_gain	1.0000
17:42207736:A:T	acceptor_gain	1.0000

AlphaMissense

5207 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:42202775:A:G	I704T	1.000
17:42202791:A:G	Y699H	1.000
17:42207610:T:A	K675N	1.000
17:42207610:T:G	K675N	1.000
17:42207638:A:G	L666P	1.000
17:42207659:C:G	R659P	1.000
17:42207674:C:G	R654P	1.000
17:42207701:G:C	P645R	1.000
17:42207701:G:T	P645H	1.000
17:42207702:G:A	P645S	1.000
17:42207702:G:T	P645T	1.000
17:42207707:A:G	L643P	1.000
17:42210186:A:G	W631R	1.000
17:42210186:A:T	W631R	1.000
17:42210188:G:T	A630D	1.000
17:42210189:C:G	A630P	1.000
17:42210191:A:T	I629N	1.000
17:42210194:G:A	T628I	1.000
17:42210200:C:T	G626D	1.000
17:42210201:C:G	G626R	1.000
17:42210203:C:A	G625V	1.000
17:42210203:C:T	G625D	1.000
17:42210204:C:G	G625R	1.000
17:42210213:A:G	S622P	1.000
17:42210215:T:A	D621V	1.000
17:42210216:C:A	D621Y	1.000
17:42210216:C:G	D621H	1.000
17:42210217:A:C	S620R	1.000
17:42210217:A:T	S620R	1.000
17:42210218:C:A	S620I	1.000

dbSNP variants (sampled 300 via entrez): RS1000031391 (17:42275922 C>A,T), RS1000065696 (17:42276380 G>A,C), RS1000091526 (17:42199715 G>A), RS1000134836 (17:42268633 T>G), RS1000144168 (17:42282724 C>A), RS1000169291 (17:42237952 C>T), RS1000177069 (17:42283011 A>C), RS1000233049 (17:42214828 C>A,T), RS1000267014 (17:42231155 C>T), RS1000269340 (17:42257731 A>G), RS1000330321 (17:42244777 C>T), RS1000356067 (17:42244527 A>G), RS1000400701 (17:42231246 T>A,C), RS1000416868 (17:42276176 G>A), RS1000424638 (17:42289094 T>C)

Disease associations

OMIM: gene MIM:604260 | disease phenotypes: MIM:245590, MIM:618985

GenCC curated gene-disease

Disease	Classification	Inheritance
growth hormone insensitivity syndrome with immune dysregulation	Definitive	Semidominant
growth hormone insensitivity with immune dysregulation 1, autosomal recessive	Strong	Autosomal recessive
growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant	Strong	Autosomal dominant
growth hormone insensitivity syndrome	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
growth hormone insensitivity with immune dysregulation 1, autosomal recessive	Definitive	AR
growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant	Moderate	AD

Mondo (4): growth hormone insensitivity with immune dysregulation 1, autosomal recessive (MONDO:0100211), growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant (MONDO:0100219), growth hormone insensitivity syndrome with immune dysregulation (MONDO:0100210), growth hormone insensitivity syndrome (MONDO:0015892)

Orphanet (1): Laron syndrome with immunodeficiency (Orphanet:220465)

HPO phenotypes

57 total (30 of 57 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000212	Gingival overgrowth
HP:0000225	Gingival bleeding
HP:0000252	Microcephaly
HP:0000421	Epistaxis
HP:0000790	Hematuria
HP:0000823	Delayed puberty
HP:0000824	Decreased response to growth hormone stimulation test
HP:0000964	Eczematoid dermatitis
HP:0000967	Petechiae
HP:0000978	Bruising susceptibility
HP:0000979	Purpura
HP:0001324	Muscle weakness
HP:0001508	Failure to thrive
HP:0001620	Abnormally high-pitched voice
HP:0001824	Weight loss
HP:0001873	Thrombocytopenia
HP:0001875	Decreased total neutrophil count
HP:0001876	Pancytopenia
HP:0001882	Decreased total leukocyte count
HP:0001892	Abnormal bleeding
HP:0001903	Anemia
HP:0001945	Fever
HP:0001974	Increased total leukocyte count
HP:0002027	Abdominal pain
HP:0002039	Anorexia
HP:0002098	Respiratory distress
HP:0002321	Vertigo
HP:0002608	Celiac disease

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST001725_55	Inflammatory bowel disease	6.000000e-22
GCST003602_13	Inflammatory bowel disease	2.000000e-09
GCST004131_42	Inflammatory bowel disease	2.000000e-17
GCST004132_58	Crohn’s disease	2.000000e-11
GCST004133_53	Ulcerative colitis	1.000000e-10
GCST005038_98	Allergic disease (asthma, hay fever or eczema)	1.000000e-09
GCST007995_3	Asthma (childhood onset)	5.000000e-09
GCST009191_13	Paracentral lobule volume	8.000000e-06
GCST009720_67	Asthma	2.000000e-08
GCST010042_25	Asthma	3.000000e-11
GCST90002388_497	Lymphocyte count	6.000000e-09
GCST90002389_233	Lymphocyte percentage of white cells	4.000000e-10
GCST90002399_241	Neutrophil percentage of white cells	5.000000e-11
GCST90014325_64	Asthma	3.000000e-09
GCST90020024_517	A body shape index	2.000000e-08
GCST90020025_1437	Waist-to-hip ratio adjusted for BMI	8.000000e-13
GCST90020027_459	Waist-hip index	3.000000e-13
GCST90020029_484	Waist circumference adjusted for body mass index	5.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C537871	Laron syndrome type 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL4523625 (PROTEIN FAMILY), CHEMBL4523698 (PROTEIN-PROTEIN INTERACTION), CHEMBL5817 (SINGLE PROTEIN), CHEMBL6196141 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 2,743 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL413376	SURAMIN HEXASODIUM	3	2,743

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

3 measured of 3 human assays (3 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
4-(Nonanamidomethyl)-1,2-phenylene bis(dihydrogen phosphate) (6b)	IC50	24900 nM
4-((8-Methylnonanamido)methyl)-1,2-phenylene bis(dihydrogen phosphate) (6a)	IC50	26400 nM
2-Methoxy-4-(nonanamidomethyl)phenyl dihydrogen phosphate (3b)	IC50	98000 nM

ChEMBL bioactivities

68 potent at pChembl≥5 of 73 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.37	Kd	4.225	nM	CHEMBL5653589
8.35	ED50	4.463	nM	CHEMBL5653589
7.70	EC50	20	nM	CHEMBL578201
7.40	EC50	40	nM	CHEMBL570002
7.40	EC50	40	nM	CHEMBL569720
7.38	Kd	42	nM	CHEMBL3358611
6.84	Ki	145.8	nM	CHEMBL3358611
6.81	IC50	154	nM	CHEMBL4088092
6.70	Ki	200	nM	CHEMBL6161430
6.66	IC50	220	nM	CHEMBL4104462
6.63	IC50	234	nM	CHEMBL4103576
6.62	IC50	240	nM	CHEMBL4085646
6.58	IC50	260	nM	CHEMBL4104019
6.57	IC50	270	nM	CHEMBL4080219
6.55	IC50	280	nM	CHEMBL4066274
6.54	IC50	290	nM	CHEMBL4086096
6.48	IC50	330	nM	CHEMBL4077592
6.46	IC50	350	nM	CHEMBL4093849
6.41	IC50	390	nM	CHEMBL4080740
6.40	Ki	400	nM	CHEMBL5395962
6.34	IC50	460	nM	CHEMBL4075745
6.28	Ki	520	nM	CHEMBL6169609
6.28	Ki	530	nM	CHEMBL6132917
6.23	Ki	590	nM	CHEMBL6169593
6.22	Ki	600	nM	CHEMBL4549938
6.21	IC50	620	nM	CHEMBL4062751
6.18	IC50	660	nM	CHEMBL4076474
6.17	Ki	670	nM	CHEMBL6148327
6.17	Ki	680	nM	CHEMBL6146875
6.10	Ki	800	nM	CHEMBL5428281
6.10	Ki	800	nM	CHEMBL6173206
6.00	Ki	1000	nM	CHEMBL5403493
6.00	Ki	1000	nM	CHEMBL5402407
6.00	Ki	1000	nM	CHEMBL6150217
5.89	Ki	1300	nM	CHEMBL5438554
5.85	IC50	1400	nM	CHEMBL4483038
5.80	Ki	1600	nM	CHEMBL5416509
5.80	Ki	1600	nM	CHEMBL5398037
5.77	Ki	1700	nM	CHEMBL5395896
5.75	Ki	1800	nM	CHEMBL6170089
5.70	Ki	2000	nM	CHEMBL5396273
5.68	Ki	2100	nM	CHEMBL5430356
5.62	Ki	2400	nM	CHEMBL6165055
5.60	IC50	2500	nM	CHEMBL1253351
5.60	Ki	2500	nM	CHEMBL5419146
5.55	Ki	2800	nM	CHEMBL1829862
5.54	IC50	2900	nM	CHEMBL4555061
5.51	Ki	3100	nM	CHEMBL5395196
5.47	Ki	3400	nM	CHEMBL2023989
5.44	Ki	3600	nM	CHEMBL6152739

PubChem BioAssay actives

56 with measured affinity, of 157 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149504: Binding affinity to human STAT5A/STAT5B incubated for 45 mins by Kinobead based pull down assay	kd	0.0042	uM
3-[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-methyl-5-[(5-methyl-1H-pyrazol-3-yl)amino]pyrazine-2-carbonitrile	446092: Inhibition of erythropoietin-stimulated STAT5 expressed in human U2OS cells	ec50	0.0200	uM
3-[[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]amino]-5-[(5-methyl-1H-pyrazol-3-yl)amino]pyrazine-2-carbonitrile	446092: Inhibition of erythropoietin-stimulated STAT5 expressed in human U2OS cells	ec50	0.0400	uM
3-[[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]amino]-6-methyl-5-[(5-methyl-1H-pyrazol-3-yl)amino]pyrazine-2-carbonitrile	446092: Inhibition of erythropoietin-stimulated STAT5 expressed in human U2OS cells	ec50	0.0400	uM
4-[[2-[(4-chlorophenyl)methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]-[(3,5-ditert-butylphenyl)methyl]amino]-2-hydroxybenzoic acid	1171627: Binding affinity to full-length His-tagged STAT5B (unknown origin) by surface plasmon resonance assay	kd	0.0420	uM
[4-[[[2-[6-(phenylcarbamoyl)naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.1540	uM
[4-[[[2-[6-[(4-fluorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2200	uM
[4-[[[2-[6-[(3-fluorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2340	uM
[4-[[[2-[6-[(4-bromophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2400	uM
[4-[[[2-[6-[(3-chlorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2600	uM
[4-[[[2-[6-[(4-chlorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2700	uM
[4-[[[2-[4-(phenylcarbamoyl)phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2800	uM
[4-[[[2-[6-[(3-bromophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.2900	uM
[4-[[[2-[4-[(4-chlorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.3300	uM
[4-[(8-methylnonanoylamino)methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1801347: Fluorescence Polarization Assay from Article 10.1021/acschembio.5b00817: “Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.”	ki	0.3400	uM
[4-[[[2-[4-[(4-fluorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.3500	uM
[4-[(nonanoylamino)methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1801347: Fluorescence Polarization Assay from Article 10.1021/acschembio.5b00817: “Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.”	ki	0.3900	uM
[4-[[[2-[4-[(4-bromophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.3900	uM
[[2-[[(2S)-1-[(2S)-2-[1,3-benzothiazol-5-yl-[3-[5-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]pent-4-ynylamino]-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	0.4000	uM
[4-[[[2-[4-[(3-chlorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.4600	uM
4-[[5-(4-fluorophenyl)tetrazol-1-yl]methylamino]-1,2,5-oxadiazole-3-carboxylic acid	1559612: Binding affinity to MBP-tagged recombinant STAT5b-SH2 domain (unknown origin) using carboxyfluoresceine-labeled phosphotyrosine octapeptide incubated for 12 hrs by fluorescence polarization assay	ki	0.6000	uM
[4-[[[2-[4-[(3-fluorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.6200	uM
[4-[[[2-[4-[(3-bromophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485961: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5B SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	0.6600	uM
[[2-[[(2S)-1-[(2S)-2-[1-benzothiophen-5-yl-[3-[5-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]pent-4-ynylamino]-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	0.8000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-naphthalen-2-ylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	1.0000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	1.0000	uM
[[2-[[(2S)-1-[(2S)-2-[1,3-benzothiazol-5-yl-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	1.3000	uM
4-(tetrazol-1-ylmethylamino)-1,2,5-oxadiazole-3-carboxylic acid	1559612: Binding affinity to MBP-tagged recombinant STAT5b-SH2 domain (unknown origin) using carboxyfluoresceine-labeled phosphotyrosine octapeptide incubated for 12 hrs by fluorescence polarization assay	ic50	1.4000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	1.6000	uM
[[2-[[(2S)-3-(4-bromophenyl)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	1.6000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-3-(4-fluorophenyl)-1-oxopropan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	1.7000	uM
[[2-[[(2S)-1-[(2S)-2-[1-benzofuran-5-yl-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	2.0000	uM
[[2-[[(2S)-1-[(2S)-2-[(4-bromophenyl)-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	2.1000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	2.5000	uM
octasodium;4-[[3-[[3,5-bis[(2,4-disulfonatophenyl)carbamoyl]phenyl]carbamoylamino]-5-[(2,4-disulfonatophenyl)carbamoyl]benzoyl]amino]benzene-1,3-disulfonate	1486489: Inhibition of 5-carboxyfluorescein-GpYLVLDKW-OH binding to STAT5B SH2 domain (unknown origin) pre-incubated for 1 hr before fluorescent-labelled peptide addition by fluorescence polarization assay	ic50	2.5000	uM
4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,4,6-trimethylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid	658686: Displacement of 5-carboxyfluorescein-labeled GpYLVLDKW from the STAT5b-SH2 domain after 15 mins by fluorescent polarization assay	ki	2.8000	uM
4-[(5-benzyltetrazol-1-yl)methylamino]-1,2,5-oxadiazole-3-carboxylic acid	1559612: Binding affinity to MBP-tagged recombinant STAT5b-SH2 domain (unknown origin) using carboxyfluoresceine-labeled phosphotyrosine octapeptide incubated for 12 hrs by fluorescence polarization assay	ic50	2.9000	uM
[[2-[[(1S)-1-cyclopropyl-2-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	3.1000	uM
4-[(4-cyclohexylphenyl)methyl-[2-[(4-methylphenyl)sulfonyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetyl]amino]-2-hydroxybenzoic acid	658686: Displacement of 5-carboxyfluorescein-labeled GpYLVLDKW from the STAT5b-SH2 domain after 15 mins by fluorescent polarization assay	ki	3.4000	uM
2-hydroxy-4-[[4-[4-(3-methoxycarbonylphenyl)phenyl]phenyl]methyl-[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]benzoic acid	658686: Displacement of 5-carboxyfluorescein-labeled GpYLVLDKW from the STAT5b-SH2 domain after 15 mins by fluorescent polarization assay	ki	3.8000	uM
[[2-[[(1S)-2-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	4.0000	uM
4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(4-phenylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid	658686: Displacement of 5-carboxyfluorescein-labeled GpYLVLDKW from the STAT5b-SH2 domain after 15 mins by fluorescent polarization assay	ki	4.1000	uM
[[2-[[(2S)-1-[(2S)-2-[(4-chlorophenyl)-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	4.2000	uM
4-[(3,5-ditert-butylphenyl)methyl-[2-[methyl-(2,4,6-trimethylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid	1171625: Inhibition of STAT5B SH2 domain (unknown origin)-5-FAM-GpYLVLDKW interaction compound treated for 15 mins by fluorescent polarization assay	ki	4.7700	uM
4-[[4-[4-(4-carbamoylphenyl)phenyl]phenyl]methyl-[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid	658686: Displacement of 5-carboxyfluorescein-labeled GpYLVLDKW from the STAT5b-SH2 domain after 15 mins by fluorescent polarization assay	ki	4.8000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-(4-phenylphenyl)carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	5.2000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[3-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	6.1000	uM
[[2-[[(2S)-1-[(2S)-2-(3,4-dihydro-2H-quinoline-1-carbonyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	6.2000	uM
[[2-[[(2S)-3,3-dimethyl-1-[(2S)-2-[methyl(phenyl)carbamoyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027879: Binding affinity to STAT5B (unknown origin) assessed as inhibition constant by FP assay	ki	6.2000	uM
2-hydroxy-4-[[2-[methyl-(2,4,6-trimethylphenyl)sulfonylamino]acetyl]-(naphthalen-2-ylmethyl)amino]benzoic acid	1171625: Inhibition of STAT5B SH2 domain (unknown origin)-5-FAM-GpYLVLDKW interaction compound treated for 15 mins by fluorescent polarization assay	ki	6.6200	uM

CTD chemical–gene interactions

85 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	9
tofacitinib	decreases reaction, increases phosphorylation, decreases phosphorylation	4
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, increases abundance, increases expression	3
bisphenol A	decreases expression, decreases methylation, increases methylation	2
WP1066	decreases phosphorylation	2
(+)-JQ1 compound	decreases phosphorylation, affects binding, decreases reaction, increases reaction, affects localization (+1 more)	2
Arsenic Trioxide	decreases expression, decreases activity, decreases phosphorylation	2
Vorinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Progesterone	increases phosphorylation, increases reaction, increases expression, affects localization	2
Tretinoin	decreases expression	2
2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4’,3’-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone	decreases phosphorylation	1
GSK-J4	increases expression	1
bisphenol F	decreases methylation	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-naphthoflavone	affects binding, decreases activity, decreases reaction, increases activity, increases phosphorylation	1
benzo(a)pyrene-3,6-quinone	increases phosphorylation	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	decreases expression	1
nickel sulfate	increases expression	1
benzo(a)pyrene-1,6-quinone	increases phosphorylation	1
tamibarotene	decreases expression	1
norcantharidin	decreases phosphorylation	1
mono(2-ethyl-5-oxohexyl)phthalate	decreases methylation, increases abundance, increases expression	1
CGP 52608	affects binding, increases reaction	1
RTKI cpd	decreases activity, decreases reaction, increases activity, increases phosphorylation	1
entinostat	decreases expression	1
AG 1879	decreases activity, decreases reaction, increases phosphorylation	1

ChEMBL screening assays

55 unique, capped per target: 55 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4362110	Binding	Effect on STAT5a/b at Y694/Y699 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer. — Eur J Med Chem

Cellosaurus cell lines

15 cell lines: 10 cancer cell line, 5 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8CI	HEK-Blue TPO	Transformed cell line	Female
CVCL_B2HL	Abcam HeLa STAT5B KO	Cancer cell line	Female
CVCL_B8QB	Abcam HCT 116 STAT5B KO	Cancer cell line	Male
CVCL_B9SS	Abcam A-549 STAT5B KO	Cancer cell line	Male
CVCL_C3ES	NK-NJ	Cancer cell line	Male
CVCL_D2HC	Abcam MCF-7 STAT5B KO	Cancer cell line	Female
CVCL_D8BN	Ubigene A-549 STAT5B KO	Cancer cell line	Male
CVCL_D8WH	Ubigene HCT 116 STAT5B KO	Cancer cell line	Male
CVCL_D9TA	Ubigene HEK293 STAT5B KO	Transformed cell line	Female
CVCL_E0Q6	Ubigene HeLa STAT5B KO	Cancer cell line	Female

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00368173	PHASE2/PHASE3	COMPLETED	IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
NCT00571727	PHASE2/PHASE3	COMPLETED	Long-Term Treatment With rhIGF-1 in GHIS